You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on lung cancer.
Two recent acquisitions have resulted in the swift launch of two assays, one for the clinic and another for research use, as the firm's original test finally nears validation.
The company reported a net loss of $8.0 million, or $.15 per share, as it saw increased costs associated with its transition to commercial test provision.
Researchers re-examined whole-genome and whole-transcriptome sequencing TCGA studies from 33 cancer types and found unique microbial signatures.
The firm posted $29.7 million in revenues, up about 15 percent from $25.8 million in Q4 2018 and slightly above the analysts' average estimate of $29.5 million.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
Foundation Medicine's liquid biopsy test will be used in the third stage of SCRUM-Japan, which focuses on advanced cancer patientsin Japan and other Asian countries.
The diagnostic firm has agreed with Streck to incorporate its blood collection tubes into sample collection protocols for its genomic lung cancer tests.
The firm presented the results of an internal validation study earlier this month at a conference, which applied the amplicon-based tool in hematological cancers.
The partners will extend the lung cancer biomarker study to countries in and outside Europe, and see if liquid biopsy could offer benefits to tissue-based testing.
The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.